Will the Approval of Inflectra be a Biosimilar Adoption Tipping Point?
June 9, 2016
Nicole Gray
BioPharma Dive
Axinn counsel Stacie Ropka was quoted in the BioPharma Dive article, “Will the Approval of Inflectra be a Biosimilar Adoption Tipping Point?”
Click here to access the article.